Innovent Biologics presents results from DREAMS-1 phase 3 study of mazdutide in Chinese adults with T2D at ADA Scientific Sessions: San Francisco Thursday, June 26, 2025, 14:00 Hr ...

Doctors should provide high quality, evidence based care reflecting individual preferences and needs, regardless of weight, argue Juan Franco and colleagues Doctors have traditionally recommended ...

"In patients with diabetes and severe CKD, an HbA1c range of 6.7–7.1% was linked to the lowest risk of complications. Risks of cardiovascular events rose at HbA1c ≥7.2% and <5 ...

DREAMS-2: A Phase 3 study comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on ...

BMI and WC were differentially associated with microvascular and macrovascular complications among patients with type 2 diabetes.